Investor Centre

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce that Bronchitol® is the subject of three presentations at the 26th annual North American Cystic Fibrosis Conference to be held in Orlando, Florida from October 10th – 13th.  These presentations focus on new analyses of patient subgroups in the Phase 3 clinical trials.

The abstracts are available on the NACF conference website at: https://www.nacfconference.org/

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received notification from the German Patent Office that the European Patent for both Aridol® and Bronchitol® has been extended by five years.

The extension to the patent, through the granting of a Supplementary Protection Certificate (SPC) is for the maximum allowable period of 5 years which will see the Aridol and Bronchitol patent extended from 24th February 2015 to 23rd February 2020.

A drug discovered and developed in Australia has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of cystic fibrosis: one of the world’s most common life-shortening genetic diseases.

Bronchitol® (mannitol) is the first of a new class of cystic fibrosis medicines designed to tackle one of the fundamental problems that leads to loss of lung function.  It has been the subject of one of the largest clinical trial programs undertaken in cystic fibrosis - conducted in over 600 patients in 10 countries around the world and co-ordinated by scientists based in Australia.